Kidney Neoplasm clinical trials at UC Davis
3 research studies open to eligible people
Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18 years and up
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the most recent regimen (either adjuvant monotherapy or first-line in combination with anti-CTLA-4 or VEGFR-TKI), with no more than 1 prior regimen in the metastatic setting.
Sacramento, California and other locations
XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18 years and up
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Sacramento, California and other locations
Project: Every Child for Younger Patients With Cancer
“A REGISTRY, ELIGIBILITY SCREENING, BIOLOGY AND OUTCOME STUDY”
open to eligible people ages up to 25 years
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Sacramento, California and other locations
Our lead scientists for Kidney Neoplasm research studies include Marcio H. Malogolowkin.
Last updated: